Outliers - this one is for you, zizou [Regulatives / Guidelines]

posted by ElMaestro  – Denmark, 2021-10-31 09:01 (392 d 02:00 ago) – Posting: # 22662
Views: 897

Hi all,

some mentally deranged weirdo published a paper in the DIA journal Therapeutic Innovation & Regulatory Science. Apparently the paper makes inference about the type I error when outlier removal takes place as described in the Canadian guidance. The author writes:

"A user named “zizou” asked a question on an internet forum in 2019 [6]; paraphrased, the question was: Wouldn’t such an outlier exclusion practice result in decreased variability without affecting the expected geometric mean ratio of Test and Reference and thus lead to increased type I error (patient’s risk, risk of declaring bioequivalence for a bioinequivalent product)?"

If I am not mistaken the author is referring to this post from zizou.

The conclusion is pretty clear - zizou was entirely correct in expressing that concern. And the author is grateful :ok: :clap:. The ball is in HC's court now and the final word on this matter has not been said.

Pass or fail!

Complete thread:

UA Flag
 Admin contact
22,417 posts in 4,692 threads, 1,596 registered users;
22 visitors (0 registered, 22 guests [including 16 identified bots]).
Forum time: 11:02 CET (Europe/Vienna)

To know that we know what we know,
and to know that we do not know what we do not know,
that is true knowledge.    Nicolaus Copernicus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz